Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?This is a plain language summary explaining the results of a study assessing a treatment, called evinacumab, for children with a condition called homozygous familial hypercholesterolemia, also known as HoFH. HoFH is a rare genetic disorder that makes the liver less able to remove ‘bad’cholesterol (called low-density lipoprotein cholesterol, or LDL-C) from the body. High levels of LDL-C increase the risk of early development of serious heart problems. Only a small number of options are available to treat children with HoFH, and these do not always work well. Evinacumab is approved in the European Union, United Kingdom, Canada, and the USA as the first medicine approved for children with HoFH aged 5 to 11 years as an add-on to other therapies that lower LDL-C. In Japan, evinacumab is also approved for treatment of people with HoFH when given with other LDL-C-lowering therapies. Evinacumab was recently approved to treat HoFH in Brazil and Israel.What were the results of the study?Children with HoFH aged 5 to 11 years treated with evinacumab every 4 weeks for 24 weeks had LDL-C levels in their blood that were almost half what they were before treatment was started.The reduction in LDL-C was seen as early as 1 week after treatment was started and was maintained through 24 weeks of treatment.Overall, evinacumab was generally well accepted by most of the children in the study. Side effects were similar to those seen in adults and adolescents with HoFH. The most common side effects in children were throat pain, stomach pain, diarrhea, nausea,vomiting, headache, and symptoms like those seen in a common cold.What do the results mean?This study showed that evinacumab lowered ‘bad’ cholesterol in children of 5 to 11 years with HoFH.Clinical trial number: NCT04233918
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".